Sensitive multiple myeloma disease monitoring by mass spectrometry

Barnidge, D. R. et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J. Proteome Res. 13 , 1419–1427 (2014). Article CAS Google Scholar Santockyte, R. et al. High-throughput therapeutic antibody interference-free high-resolution mass spectrometry assay for monitoring M-proteins in multiple myeloma. Anal. Chem. 93 , 834–842 (2021). Article CAS Google Scholar Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379 , 1811–1822 (2018). Article CAS Google Scholar Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 , e538–e548 (2014). Article Google Scholar Mills, J. R. et al. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 132 , 670–672 (2018). Article CAS Google Scholar Moore, L. M., Cho, S. & Thoren, K. L. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin. Chim. Acta 492 , 91–94 (2019). Article CAS Google Scholar Zajec, M. et al. Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J. Proteome Res . 17 , 1326–1333 (2018). Article CAS Google Scholar Mills, J. R. et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin. Chem. 62 , 1334–1344 (2016). Article CAS Google Scholar Waldmann, T. A. & Strober, W. Metabolism of immunoglobulins. Prog. Allergy 13 , 1–110 (1969). CAS PubMed Google Scholar Hall, S. L., Tate, J., Gill, D. & Mollee, P. Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin. Biochem. Rev. 30 , 113–118 (2009). PubMed PubMed Central Google Scholar Download references